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Abstract
Genetic alterations in specific driver genes lead to disruption of cellular pathways and are critical
events in the instigation and progression of hepatocellular carcinoma. As a prerequisite for
individualized cancer treatment, we sought to characterize the landscape of recurrent somatic
mutations in hepatocellular carcinoma. We performed whole exome sequencing on 87
hepatocellular carcinomas and matched normal adjacent tissues to anaverage coverage of 59x. The
overall mutation rate was roughly 2 mutations per Mb, with a median of 45 non-synonymous
mutations that altered the amino acid sequence (range 2 to 381). We found recurrent mutations in
several genes with high transcript levels: TP53 (18%), CTNNB1 (10%), KEAP1 (8%), C16orf62
(8%), MLL4(7%) and RAC2 (5%). Significantly affected gene families include the nucleotide-
binding domain and leucine rich repeat containing family, calcium channel subunits, and histone
methyltransferases. In particular, the MLL family of methyltransferases for histone H3 lysine 4
were mutated in 20% of tumors.
Conclusion—The NFE2L2-KEAP1 and MLL pathways are recurrently mutated in multiple
cohorts of hepatocellular carcinoma.
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INTRODUCTION
Hepatocarcinogenesis is instigated by copy number alterations, mutations and chromosomal
rearrangements that activate oncogenes or inactivate tumor suppressors. Previous genetic
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characterization of hepatocellular carcinoma (HCC) has indicated significant heterogeneity
among tumors, which has hampered the development of targeted therapy. Genomic and
transcriptomic profiling studies have attempted to classify tumor molecular subgroups and
have implicated several signaling pathways that are mutated in HCC (1–3). The Wnt β-
catenin signaling pathway members, CTNNB1, AXIN1 and AXIN2 are collectively mutated
in up to half of tumors. The most frequently mutated tumor suppressor is TP53, which has
mutations in over 20% of tumors. Over half of hepatocellular carcinomas harbor gains of
chromosome 1q and 8q, which include candidate oncogenes MCL1, SHC1, MYC and
COPS5/JAB1, among hundreds of other genes(4–8).
To date, studies of the mutational spectrum of HCC have focused on a limited number of
candidate genes. Advances in genome sequencing technologies have enabled the
simultaneous analysis of thousands of expressed genes accelerating the search for additional
novel and recurrently mutated genes (9–14). Recent studies have identified the ATP-
dependent nucleosome remodeling enzymes, ARID1A and ARID2, to be mutated in
approximately 15% and 5% of tumors, respectively (11–14). A regulator of the redox
signaling pathway, NFE2L2, is mutated in 6% of tumors (12). Other genes mutated at
greater than 3% frequency include RPS6KA3, IL6ST, NRAS, KRAS, PIK3CA, PTEN,
SAMD9L, DMXL1 and NLRP1(11, 13, 15).
The genetic heterogeneity of HCC has complicated our understanding of the molecular basis
of this disease. In order to further define theimportant recurrent and clinically
actionablemutations in HCC, we embarked on a large-scale study of 87 tumors that was
powered to detect mutated genes at a population prevalence of at least 10%. We
hypothesized that multiple component genes of certain signaling pathways could be
recurrently mutated in hepatocellular carcinoma.
EXPERIMENTAL PROCEDURES
Human subjects
Subjects were identified and informed consent was obtained from consecutive patients
undergoing surgical resection for confirmed HCC at the University Health Network
(Toronto, Canada) and the University of North Carolina. Five additional tumor specimens
were procured from the Cooperative Human Tissue Network. All surgical specimens were
processed according to established institutional HCC-tumor banking protocols. In brief,
fresh surgical specimens underwent immediate gross pathologic examination by experienced
liver pathologists. Samples were obtained from viable tumor and non-tumor liver >2 cm
away from the primary lesion. Tumors with evidence of prior therapy, such as
radiofrequency ablation or trans-arterial chemo-embolization were excluded. Tissue samples
were bisected with half of the tissue stored in liquid nitrogen and the mirror sample retained
for histologic confirmation. All tumor samples were histologically assessed for diagnosis
and cellularity and non-tumor liver samples were confirmed to be free of tumor cells.
DNA extraction and sequencing libraries
Tissue samples were thawed and weighed prior to homogenization. Genomic DNA and
RNA was extracted with the Qiagen AllPrep kit (Valencia, CA) and quality was assessed on
2% agarose gel. Genomic DNA for exome capture and sequencing was prepared using either
SureSelect Target Enrichment System for Illumina Paired-End Sequencing Library (Agilent
Technologies, Santa Clara, CA) according to manufacturer’s instructions (protocol versions
1.2, May 2011 and 1.3.1, February 2012) or equivalent enzymes (New England Biolabs,
Ipswich, MA) and Agilent’s protocol (version 2.0.1, May 2010). Briefly, 2–3 micrograms of
genomic DNA were sheared on Covaris S220 (Woburn, MA) to 150–200 bp target size with
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the following instrument settings: 10% duty cycle; intensity 5; 200 cycles per burst; 6 cycles
of 60 seconds each in frequency sweeping mode. Sheared fragments were ligated to
Illumina’s adapters and enriched by 5–6 cycles of amplification. Five hundred nanograms of
amplified libraries were incubated with Agilent’s whole exome capture oligos for 24h at
65°C. Hybridized fragments were captured with streptavidin-coated beads, eluted, and
amplified by 10–12 cycles of PCR utilizing either one of 12 Agilent’s indexed primers or
not indexed SureSelect GA PCR primers). Prepared libraries were pooled in batches of 4
and sequenced on Illumina HiSeq 2000 (San Diego, CA) instrument generating 100 bp
paired end reads. Alternatively, individual libraries were sequenced on Illumina GAII
instrument generating 76 bp paired end reads.
We enriched for protein coding regions with the Agilent AllExon version 1 sequence capture
baits for 10 tumors and matched normals, and with the Nimblegen Human exome version 1
sequence capture baits for 5 tumors and matched normals. These captured libraries were
sequenced on the Illumina Genome Analyzer II to an average of 4.8x and 5.8x, respectively.
An additional 72 tumors and matched normals were captured on the Agilent AllExon
version 4 sequence capture baits, and sequenced in pools of 4 samples with the
IlluminaHiSeq 2000 to an average of 59x coverage (Supplementary Figure 1).
Bioinformatics sequence analysis
Sequences were mapped to the human genome (NCBI37/hg19), excluding alternative
haplotype chromosomes, using the Bowtie 2 alignment algorithm (16). Alignments were
refined using The Genome Analysis ToolKitto mark PCR duplicate reads and perform base
quality recalibration(17, 18). Alignments from each tumor and matched normal were then
analyzed by the MuTect algorithm(19, 20). In brief, MuTect includes a preprocessing step
for sequence read qualities, a Bayesian classifier to assess the posterior probability of
somatic mutations, and post-processing of candidate mutations. Somatic mutations were
assigned to transcript and amino acid coordinates using the ANNOVAR software suite(21).
Availability of genetic sequencing data
Binary sequence alignment map files (BAM files) have been deposited in the National
Center for Biotechnology Information dbGAP database.
Significantly mutated genes and pathways
The MutSig software version 1.5 identified the list of significantly mutated genes among 87
hepatocellular carcinomas (20)(https://confluence.broadinstitute.org/display/CGATools/
MutSig). Genes that harbored a greater number of mutations than expected by chance were
detected with a binomial test. For each gene, the observed number of mutations across the
87 tumors was compared to the expected number based on the background mutation rates
and the covered bases in all samples. The binomial probabilities were adjusted to False
Discovery Rate q-values with the Benjamini-Hochberg procedure and reported in Table 1.
Gene families were downloaded in May 2012 from the HUGO Gene Nomenclature
Committee database (22)(http://www.genenames.org/genefamilies/a-z). For each gene
family, we tested for an enrichment of mutations in the genes within the family relative to
the genes outside of the family. For each individual, we calculated the per-base mutation
rate among the exons of the genes within the gene family and among the exons of the genes
outside of the gene family. We then tested whether the average mutation rate within a gene
family was higher than the average mutation rate for genes outside the family using a one-
sided, paired t-test.
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RNA Isolation from Tissue samples and Quantitative Real-time PCR
Total RNA was prepared using Qiagen AllPrep kit (Qiagen, Valencia, CA) and quality was
assessed on 2% agarose gel. MVP™ Human Liver Total RNA pool (Agilent Technologies,
Santa Clara, CA) was introduced as a standard control. cDNA was synthesized using 200ng
random primers (Thermo Scientific, Rockford, IL) and 200U M-MLV Reverse
Transcriptase (Life Technologies, Grand Island, NY) from 2μg of each total RNA sample
according to the manufacturer’s instructions. All samples within an experiment were reverse
transcribed under the same condition, the resulting cDNA diluted 1:5 in nuclease-free water
and stored in aliquots at −20°C until used. Real-time PCR with SYBR green detection was
performed in Light Cycler 480 System (Roche Applied Science, Indianapolis, IN) in a total
reaction volume of 20 μL in 384-well plate. Each reaction contained 5μL of diluted cDNA,
500nM of each primer (as listed in Supplementary Table 1) and 1× LightCyclerR 480 SYBR
Green I master mix. The real-time PCR running protocol consisted of (1) 5 min pre-
incubation at 95°C; (2) amplification (10 s at 95°C; 10 s at 60°C; 15 s at 72°C); (3) melting
curve (10 s at 95°C, 65–97°C at at 2.5°C/s –1 and a continuous fluorescent measurement);
and (4) 10 s cooling at 40°C. Relative quantitative analysis was carried out according to the
2−ΔΔCt method(23).
Statistical analyses
Descriptive characteristics of genetic and clinical variables were reported as frequencies and
percentages for categorical variables; continuous variable were reported as medians and
range. Comparisons of frequencies between genetic and clinical variables were performed
using chi-square and Fisher’s exact test, where appropriate. Survival analyses were
performed using the Kaplan-Meier method. Univariate survival analysis was performed
using the Log-rank tests and multivariate analyses conducted using Cox proportional
hazards model.
RESULTS
Clinical characteristics of HCC specimens
Complete clinical data was available for 87 of 89 (98%) tumor samples and is shown in
Table 1. Cases included a mix of predisposing disease etiologies including 43% and 21% of
patients with hepatitis B and C, respectively. Nineteen cases had multifocal disease at the
time of surgery, however only one tumor was submitted for analysis in each case. Positive
staining for CK19 in >5% of cells was seen in 12 cases and 2 tumors were fibrolamellar
HCC. Median follow-up of cases was 33.8 months (range 3–130 months). There were 3
(3.8%) perioperative deaths within 90 days. A total of 28/87 (32%) patients died with a
mean overall survival of 80.6 months with a 5-year overall survival estimated at 76% by
Kaplan-Meier analysis. During follow-up there were a total of 44 recurrences for a median
disease-free survival of 39.1 months.
Significantly mutated genes in HCC cohort
In total, we found 5820 non-synonymous mutations and 433 nonsense mutations in these 87
tumors (average 66.1, range 4 to 362) or 2.5 mutations per Mb sequenced (Figure 1A). The
somatic mutation rate is comparable to those reported in previous studies (11–14). The
mutational bias for CpG to A/T transversions in hepatocellular carcinoma was consistent
with previous studies (Figure 1B).
We followed standard statistical analyses to discriminate driver mutations from random
mutations (19, 24). We assumed that most of the mutations in cancer genomes represent
background noise, while driver genes would be mutated more frequently than expected by
chance. We used a binomial probability to estimate the expected number of mutations for
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each sample. This probability distribution corrects for gene length, due to the assumption
that longer genes will be expected to accumulate more mutations by chance. We calculated
the background mutation rate using all of the nonsynonymous and synonymous mutations
determined in all 87 samples. For each mutated gene, we then calculated the binomial
probability of observing at least N mutations, given the background mutation rate. The p-
value was adjusted for multiple hypotheses using the Benjamini-Hochberg procedure for
controlling False Discovery Rate (FDR). In this analysis, we identified 34genes that were
significantly mutated from the discovery cohort, according to a False Discovery Rate cutoff
of 10%.
The most frequently mutated genes in this cohort were the well-known oncogene CTNNB1
(10%) and tumor suppressor, TP53 (18%)(Table 2). CTNNB1 mutations and activation of
the Wnt pathway have been associated with large (>3cm) tumors, poorly differentiated
histology, tumor invasion and metastases as well as HCV-associated HCC. TP53 mutations
have been associated with all predisposing etiologies with specific Ser249 mutations
associated with Aflatoxin B exposure. KEAP1, encoding kelch-like ECH-associated protein
1, retains NFE2L2/NRF2 in the cytosol and regulates the Keap1-Nrf2 cell defense pathway
(25). Previous studies have showed that the Keap1-Nrf2 signaling pathway mediates
protective cellular responses to oxidative and xenobiotic damage (26, 27). The roles of
IGSF3, ATAD3B and PCMTD1 have not been previously characterized in HCC.
Significant enrichment of mutations in histone methyltransferases
To further characterize the pattern of mutated genes and explore their significance of
functional pathways in HCC, we analyzed mutations within known gene families (Table 3).
Among 4 histone H3 lysine 4 methyltransferases of the MLL family, we validated 13
missense mutations by PCR and Sanger-based resequencing. We identified 2 tumors with
MLL mutations, 4 tumors with MLL2 mutations, 1 tumor with MLL3 mutations and 6 tumors
with MLL4 mutations (Figure 2A to 2D). Among the MLL gene family, the MLL2 and MLL4
genes seem to be the most likely driver genes in HCC. MLL4 encodes mixed lineage
leukemia-4, one of the MLL family of histone H3 lysine-4 (H3K4)-specific methyl
transferases. Notably, MLL4 is a recurrent hotspot for hepatitis B virus integration in nearly
12% of hepatocellular carcinoma genomes (28). MLL3 and MLL4 participate in
transcriptional coactivator complexes and are necessary for the expression of p53 target
genes in response to DNA damage (29). Knockdown of MLL4 reduces cell cycle
progression and induces apoptosis (30).
Transcript levels of recurrently mutated genes
We further sought to confirm expression level signatures of 13 recurrently mutated genes in
tumor and liver samples used for sequencing analysis. Total RNA was extracted from 49
tumor samples, 8 non-tumor liver samples from HCC patients and normal liver reference
RNA. Among the tumors selected for expression analysis, 39 had mutations in recurrently
altered genes, 10 tumors lacked mutations in the genes of interest. In the non-tumor liver
specimens of HCC cases overexpression of several genes was observed including TP53 (6/8
samples), CTNNB1 (4/8), ATAD3B (5/8), PCMTD1 (5/8), BRD9 (4/8), TTLL2 (4/8),
TMEM170A (4/8), TMEM51 (5/8) and GJA1 (3/8), while IGSF3 was underexpressed in 5/8
samples(Figure 3). Among samples with a confirmed TP53 mutation, the gene was
overexpressed in 5/9 and underexpresed in 3/9 samples. CTNNB1 was overexpressed in 7/9
tumors with mutations in this gene. KEAP1 expression levels were similar in non-tumor
liver samples compared to reference controls, but decreased expression was seen in 4/6
tumors with KEAP1 mutations. Increased expression of genes in samples harbouring
mutations was observed for CPA2 (3/6 samples), ATAD3B (1/1), PCMTD (1/1), BRD9 (5/6),
TTLL2 (2/4), TMEM170A (2/2), TMEM51 (3/3) and GJA1(2/2).
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Clinical characteristics of HCC according to mutation status
HCC arising from hepatitis C infection demonstrated a significantly higher rate of CTNNB1
mutations (62.5% vs 37.5%, p=0.038) confirming earlier reports associating mutations in b-
catenin with HCV. There was also a trend toward higher rates of microvascular invasion in
HCC with MLL gene mutations (67% vs 45%, p=0.11). Otherwise, there were no significant
associations between individual gene or gene family mutations and clinical variables
assessed.
Mutations in TP53 were associated with significantly higher rate of recurrence (89% vs
40%, p=0.006) and shorter disease-free survival (median DFS: 7.9 vs 42.9 months, p=0.001)
(Figure 4). There was a trend towards decreased overall survival status among TP53-
mutatedtumors (median OS: 26.0 vs 83.2 months, p=0.1) (Supplementary Figure 2). Tumors
harboring mutations in the MLL family were associated with a trend toward earlier
recurrence with a median disease free survival of 28.9 months for MLL mutation carriers
compared to 45.8 months for cases without MLL mutations (p=0.22) and may be associated
with a more aggressive disease phenotype(Supplementary Figure 3). A trend towards lower
rates of recurrence (12.5% vs 49.3%, p=0.060) and prolonged disease free survival (p=0.23)
was observed in cases with CTNNB1 mutations but did not reach statistical significance due
to limited power. The presence of CPA2 and KEAP1 mutations were associated with
decreased disease-free survival however these analyses lacked sufficient statistical power.
Univariate analysis of disease-free survival for all clinical and genetic variables identified
tumor size (p=0.042), multifocality (p=0.077), and p53 mutation status (p=0.001) as
significant or borderline significant predictors of DFS(Table 4). Conditional multivariable
survival analysis demonstrated that p53 mutation status was the only independent predictor
of disease-free survival with a hazard ratio (HR)=4.245 (95%CI: 1.86- 9.70 (p=0.02)).
Tumor multifocality was the only independent predictor of overall survival.
DISCUSSION
Hepatocellular carcinoma is a genetically heterogeneous disease; this molecular diversity
has led many groups to attempt to characterize HCC to improve our understanding of the
genes and pathways involved in the etiology of this disease. The goal of genomic and
transcriptomic profiling efforts in HCC is to develop a molecular classification of
hepatocellular carcinoma that identifies characteristic driver genes that either predict
prognosis or eventually could be developed as targets for tailored therapies. This study of 87
matched tumor-normal pairs more than doubles the number of HCC characterized by whole
exome sequencing, to a total of 158 tumors. Due to limited sample sizes (ranging from 10 to
27 tumors), it should not be surprising that these studies have not yielded many overlapping
genes. Indeed, larger sample cohorts with clinical follow-up data will be required to discern
the prognostic significance of recurrently mutated genes.
An interesting emerging consensus from these HCC sequencing studies is the prevalence of
mutations in chromatin regulatory enzymes. In particular, several studies have reported
mutations in the SWI/SNF-related, ATP-dependent nucleosome remodelers: ARID1A and
ARID2(11–14). We only detected 2 mutations in ARID1A(2%) and 1 mutation in ARID2
(1%), despite over 20x coverage of these genomic regions. However, our study concurs with
recent reports of mutations in the MLL family of histone H3 lysine4 methyltransferases,
which can also be disrupted by genomic integration of hepatitis B virus(14, 28). The clinical
characteristics of tumors harboring MLL gene mutations suggest that inactivation of the
MLL gene family may be associated with an aggressive tumor phenotype. However, we have
not evaluated the functional impact of these mutations on histone methylation. As more data
on the MLL gene family are collected, further studies could assess how the most frequent
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mutations may impair the enzymatic function or recruitment of these enzymes. Further work
is needed to elaborate how disrupted chromatin regulators cooperate with alterations in
known signaling pathways – such as the Wnt/beta-catenin pathway or Myc targets – in
tumor progression, cellular differentiation, or gene expression.
Woo and colleagues had previously demonstrated worse overall survival associated with p53
mutations in a cohort of predominantly Chinese HCC patients with hepatitis B virus etiology
(31). This study complements those findings by demonstrating the prognostic value of HCC
in a North American series of patients of mixed etiology (HBV/HCV). Combined, this data
demonstrates that p53 is associated with recurrence and disease-free survival, oncologic
outcomes that reflect an aspect of tumor biology, as well as overall survival, which includes
death from both HCC and the underlying liver disease. The observation of p53 as an
independent prognostic factor with an ability to predict outcomes in addition to tumor size
and number may have important clinical implications in predicting outcomes for patients
prior to treatment such as resection or transplantation.
Sorafenib represents the first molecularly targeted therapy for HCC, and the vast majority of
HCC clinical trials are currently evaluating the efficacy of tyrosine kinase inhibitors (32,
33). However, the combined analysis of whole exome sequencing from 158 tumors reveals
that no single protein kinase that is mutated at more than 5% frequency in hepatocellular
carcinoma(9–14). This scarcity of kinase mutations suggests that HCC might be rarely
susceptible to the dramatic responses to kinase inhibitors that are observed in other cancer
types(34, 35). In contrast, the frequent mutation of MLLhistone methyltransferases – as well
as ARID ATP-dependent nucleosome remodeling enzymes identified in previous studies –
suggests that epigenetic regulatory enzymes may represent important target genes in HCC.
Since most studies to date have been conducted on surgically resected tumors, we have little
knowledge about the genetic alterations that occur in either very early lesions treated with
ablative modalities as well as later stages of HCC progression that are not amenable to
surgical treatment. Our understanding of tumor evolution could be improved by more
sensitive technologies that could sequence genomic DNA from core biopsy specimens.
Another confounding issue with genomic profiling is the high rate of intra-tumor
heterogeneity. Indeed, a pioneering study demonstrated considerable clonal heterogeneity
within a single tumor lesion, with allelic frequencies as low as 13% (10).
In this series, we present the whole-exome sequencing analysis of a large diverse series of
HCC tumors and matching normal liver tissue. Our results support the genetic heterogeneity
of HCC in that most genes were mutated in few (<20%) of the samples analyzed, however
analysis of gene families have indicated potentially important pathways, including MLL and
NFE2L2-KEAP1, that are altered in subsets of tumors. Overexpression of several genes of
interest were observed in tumors with identified mutations but also in adjacent non-tumor
liver samples, which suggests a role of these genes in the pre-malignant “field-effect” that is
seen in the unaffected liver of HCC patients (36). We observed phenotypic differences in
HCC according to gene mutation status including p53 mutation status as an independent
predictor of recurrence-free survival. Several other genes of interest demonstrated trends in
time and risk of recurrence; these observations were limited by sample size and require
further investigation in larger studies. The lack of correlation between traditional prognostic
features such as tumor size, number and vascular invasion indicates that mutational profiling
may enhance our ability to develop more predictive models of tumor behavior. Further
investigation is required to enhance our understanding of the full breadth of gene mutations
in HCC and identify clinically-relevant genes and pathways that can enhance ourunder
standing of hepatocarcinogenesis and develop individualized therapy based on HCC genetic
signatures.
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Figure 1. Mutation landscape of 87 hepatocellular carcinomas
The matrix in the center of the figure represents individual mutations in patient samples,
color-coded by type of mutation, for the significantly mutated genes. The rate of
synonymous and non-synonymous mutations is displayed at the top of the matrix. The
barplot on the left of the matrix shows the number of mutations in each gene. The
percentages represent the fraction of tumors with at least one mutation in the specified gene.
The barplot to the right of the matrix displays the q-values for the most significantly mutated
genes. The purple boxplots below the matrix represent the distributions of allelic fractions
observed in each sample. The plot at the bottom represents the base substitution distribution
of individual samples, using the same categories that were used to calculate significance.
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Figure 2. Protein domain structure of histone methyltransferases
Mutations are displayed at the protein coding residues, and protein domains are indicated by
the colored blocks.
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Figure 3. Expression levels of mutated genes in hepatocellular carcinomas
Real-time PCR analysis of 13 genes differentially expressed among 49 HCC tumors(blue
dot) and 8 adjacent tissues (blue circle). Samples confirmed with target gene mutation were
highlighted in red. The mRNA expression level was normalized to zero based on normal
human liver samples. The vertical axis indicates the relative increase (+) or decrease (−)
fold-change of each tumor or adjacent sample compared with normal human liver.
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Disease-free survival according to p53 mutation status.
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Table 1
Clinical characteristics of HCC samples.
Patients N=87(%)
Male: Female 61(77):18(23)











Median tumor size (range) 6.2 (2–18)
Pathology Characteristics














Macrovascular (large vessel) 12(14)
*
-patients may have more than one predisposing condition
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Table 2
Significantly mutated genes in 87 hepatocellular carcinomas
Gene Description # patients # sites Mutation significance
(FDR q-val)
CTNNB1 Beta-catenin 20 14 <1 × 10−11
TP53 Tumor protein p53 17 14 <1 × 10−11
CPA2 Carboxypeptidase A2 (pancreatic) 8 2 3.22 × 10−6
IGSF3 Immunoglobulin superfamily, member 3 8 5 1.3 × 10−5
KEAP1 Kelch-like ECH-associated protein 1 7 7 4 × 10−4
ATAD3B ATPase, AAA domain containing 3B 4 2 2.6 × 10−3
PCMTD1 protein-L-isoaspartate (D-aspartate) O- methyltransferase domain
containing 1
3 2 8.3 × 10−3
BRD9 Bromodomain containing 9 5 2 0.017
TTLL2 Tubulin tyrosine ligase-like family, member 2 4 2 0.017
TMEM170A Transmembrane protein 170A 3 1 0.037
AR Androgen receptor 5 5 0.038
TMEM51 Transmembrane protein 51 3 1 0.042
GJA1 Gap junction protein, alpha 1, 43kDa 3 3 0.049
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Table 3
Significantly mutated gene families in 87 hepatocellular carcinomas
Symbol Family description # genes Mutation rate in family t-test (rate)
NLR Nucleotide-binding domain and leucine rich repeat containing 22 2.68E-06 0.0033
MLL Mixed lineage leukemia histone methyltransferases 5 2.85E-06 0.0037
CACN Calcium channel subunits 26 2.17E-06 0.0041
KMT Chromatin-modifying enzymes/K-methyltransferases 26 2.13E-06 0.0060
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Table 4
Predictors of disease-free survival (DFS)
Median DFS months (95%CI) Univariate Analysis1 Multivariate analysis HR2 (95%CI), p-value
P53 P=0.001
No mutation 42.9 (14–72) 4.2 (1.9- 9.7), p=0.02
Mutation (+) 7.9 (7.2–8.5)
MLL P=0.38
No mutation 42.9 (6.1–79.8)
Mutation (+) 23.1 (3.9–42.2)
B-catenin P=0.51
No mutation 27.1 (4.9–49.3)
Mutation (+) 43.0 (1–99.1)
CPA2 P=0.25
No mutation 42.9 (20.4–65.5)
Mutation (+) 15.3 (5.3–25.2)
Age P=0.16
Tumour Number P=0.08
Solitary 44.3 (10.3–78.3) 2.0(0.97–4.1), p=0.06
Multifocal 15.4 (3.0–27.3)








Well diff 39.0 (5.2–72.8)
Moderately diff 32.9 (14.5–71.5)
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